IPERIONX (IPX) Director Martin Lorraine Buys 4,100 Shares

What Happened

Martin Lorraine, a director of IPERIONX Ltd (IPX), reported an open-market/private purchase (transaction code P) of 4,100 shares on July 10, 2026 at $24.51 per share, for a reported total of $100,491. The Form 4 classifies the reported securities as "Derivative" (see footnotes), and this purchase is a buy (which many investors view as a more bullish signal than a sale).

Key Details

• Transaction date and price: 2026-07-10 at $24.51 per share; total value $100,491.
• Filing date: Form 4 filed 2026-07-13. No late-filing flag is indicated in this record.
• Shares owned after transaction: Not specified in the Form 4 (ownership total not provided).
• Footnotes of note:
  • F1: IPX ordinary shares trade on the Australian Stock Exchange (ASX).
  • F3: IPX American Depository Shares (ADS) trade on NASDAQ; 1 ADS = 10 ordinary shares.
  • F4: Example equivalence listed: 8,855 ADS = 88,550 ordinary shares.
  • F2: Separately notes vesting schedules (76,054 vest Dec 2026; 14,162 vest Dec 2027), indicating outstanding awards referenced in the filing.

Context

The Form 4 labels the securities as "Derivative," which typically means the reported instrument is not a plain share certificate (ADS or other derivative form can be reported this way). Footnotes clarify the ADS/ordinary-share relationship for IPX (1 ADS = 10 ordinary shares). The filing shows a straightforward purchase rather than an exercise, sale, or gift — purchases by directors are often watched by retail investors as a signal of insider conviction, but filings alone don't reveal motivation.